Verapamil therapy for stable exertional angina pectoris

Area of Science:

• Cardiology
• Pharmacology

Background:

• Stable exertional angina pectoris significantly impacts patient quality of life.
• Current treatments aim to reduce myocardial oxygen demand and improve coronary blood flow.

Purpose of the Study:

• To evaluate the efficacy and safety of verapamil in patients with stable exertional angina pectoris.
• To compare clinical and exercise responses to verapamil versus placebo.

Main Methods:

• A double-blind, placebo-controlled, randomized crossover study was conducted.
• 26 patients with stable exertional angina received verapamil (480 mg daily) or placebo.
• Clinical endpoints included angina attack frequency, nitroglycerin use, and exercise duration.

Main Results:

• Verapamil significantly reduced angina attack frequency (p < 0.001) and nitroglycerin consumption (p < 0.05).
• Exercise duration significantly increased with verapamil treatment (p < 0.001).
• Beneficial effects correlated with reduced heart rate-systolic blood pressure product during exercise; constipation was the main adverse effect.

Conclusions:

• Verapamil is a highly effective and safe medication for managing stable exertional angina pectoris.
• Combined evidence from multiple trials supports verapamil's utility in effort-related angina.
• The drug's benefits are linked to improved hemodynamic responses during exercise.